CLINICAL_TRIALS
ClinicalTrials.gov record update
A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST® Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Paediatric Patients
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02227992
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:35.477405+00:00
- Published At
- 2023-09-08T00:00:00+00:00
- Record Updated At
- 2023-09-08
- Results Posted At
- 2023-09-08
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Hemorrhage", "Soft Tissue Bleeding", "Hepatic Parenchyma Bleeding"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-08"- protocolSection.identificationModule.nctId
"NCT02227992"- protocolSection.identificationModule.officialTitle
"A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST\u00ae Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Paediatric Patients"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-08"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.